Podcasts about Hikma

Howie and Harlan discuss healthcare headlines including proposed changes to federal research funding, an outbreak of New World screwworm in Texas cattle, and the debate over free expression after researchers were removed from the American Diabetes Association meeting for distributing an editorial critical of federal science policies. They also examine the future of generic GLP-1 drugs, a new Medicare model for heart failure care, and a court ruling with implications for international physicians practicing in the United States. Show notes: Research Grants NIH: NOT-OD-25-132: Supporting Fairness and Originality in NIH Research Applications Akiko Iwasaki Health & Veritas Episode 192: Akiko Iwasaki: What Have We Learned About Long COVID? Stuart Buck "White House proposes new rules giving political appointees final approval on research grants" U.S. Constitution: Article II Skinny Labeling and the Supreme Court "Supreme Court Upholds Preventive Services Requirement Under ACA" "Supreme Court Rejects Colorado Law Banning 'Conversion Therapy' for L.G.B.T.Q. Minors" Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (24-889) "Hikma v. Amarin: Supreme Court Weighs Future of 'Skinny Labeling'" Value-Based Care CMS: Value-Based Care CMS: Hospital Readmission Reduction New World Screwworm CDC: New World Screwworm USDA: New World Screwworm Economic Impact Report USDA: Eradicating New World Screwworm with Sterile Insect Technique American Diabetes Association Meeting "Join the ADA in New Orleans for the 2026 Scientific Sessions" NIH Director Jay Bhattacharya Diabetes Care: "Misguided Brushes of a Pen Continue to Dismantle and Destroy Biomedical Research in the United States: We Can No Longer Afford Complacency and Fear. We Must All Act Now!" "Diabetes researchers ousted from conference after criticizing Trump" H-1B Visas Presidential Proclamation on Restriction on Entry of Certain Nonimmigrant Workers "Federal judge blocks Trump's $100,000 H-1B visa fee" "Health Care Professionals Sponsored for H-1B Visas in the US" Exchange Visitors and the J-1 Classification In the Yale School of Management's MBA for Executives program, you'll get a full MBA education in 22 months while applying new skills to your organization in real time. Yale's Executive Master of Public Health offers a rigorous public health education for working professionals, with the flexibility of evening online classes alongside three on-campus trainings. Email Howie and Harlan comments or questions.

Howie and Harlan discuss healthcare headlines including proposed changes to federal research funding, an outbreak of New World screwworm in Texas cattle, and the debate over free expression after researchers were removed from the American Diabetes Association meeting for distributing an editorial critical of federal science policies. They also examine the future of generic GLP-1 drugs, a new Medicare model for heart failure care, and a court ruling with implications for international physicians practicing in the United States. Show notes: Research Grants NIH: NOT-OD-25-132: Supporting Fairness and Originality in NIH Research Applications Akiko Iwasaki Health & Veritas Episode 192: Akiko Iwasaki: What Have We Learned About Long COVID? Stuart Buck "White House proposes new rules giving political appointees final approval on research grants" U.S. Constitution: Article II Skinny Labeling and the Supreme Court "Supreme Court Upholds Preventive Services Requirement Under ACA" "Supreme Court Rejects Colorado Law Banning 'Conversion Therapy' for L.G.B.T.Q. Minors" Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (24-889) "Hikma v. Amarin: Supreme Court Weighs Future of 'Skinny Labeling'" Value-Based Care CMS: Value-Based Care CMS: Hospital Readmission Reduction New World Screwworm CDC: New World Screwworm USDA: New World Screwworm Economic Impact Report USDA: Eradicating New World Screwworm with Sterile Insect Technique American Diabetes Association Meeting "Join the ADA in New Orleans for the 2026 Scientific Sessions" NIH Director Jay Bhattacharya Diabetes Care: "Misguided Brushes of a Pen Continue to Dismantle and Destroy Biomedical Research in the United States: We Can No Longer Afford Complacency and Fear. We Must All Act Now!" "Diabetes researchers ousted from conference after criticizing Trump" H-1B Visas Presidential Proclamation on Restriction on Entry of Certain Nonimmigrant Workers "Federal judge blocks Trump's $100,000 H-1B visa fee" "Health Care Professionals Sponsored for H-1B Visas in the US" Exchange Visitors and the J-1 Classification In the Yale School of Management's MBA for Executives program, you'll get a full MBA education in 22 months while applying new skills to your organization in real time. Yale's Executive Master of Public Health offers a rigorous public health education for working professionals, with the flexibility of evening online classes alongside three on-campus trainings. Email Howie and Harlan comments or questions.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're delving into a series of groundbreaking advancements and strategic movements reshaping the landscape of drug development and patient care. Eli Lilly's retatrutide has emerged as a significant breakthrough in obesity treatment, demonstrating a remarkable 30.3% weight reduction over two years in a Phase 3 trial. This drug, a triple agonist targeting glucagon-like peptide-1 receptors, regulates appetite and energy balance effectively. Such results not only highlight its potential as a transformative therapy for obesity but also position Eli Lilly prominently within metabolic disorder treatment landscapes. With global obesity rates on the rise, retatrutide's success could meaningfully impact public health strategies and pharmaceutical approaches to managing weight. In the oncology sector, Johnson & Johnson's acquisition of Firefly Bio for $1 billion is a strategic move aimed at enhancing their oncology pipeline with Firefly's Degrader Antibody Conjugate platform. This technology is designed to target KRAS-driven tumors, which are notoriously difficult to treat, prevalent in cancers such as pancreatic and colorectal cancer. By integrating Firefly's innovative platform, J&J aims to offer new hope for patients dealing with these challenging cancers. Turning to regulatory developments, the FDA has expanded Pfizer's Hympavzi label to include pediatric patients aged six and older with hemophilia A and B. This decision follows robust Phase 3 results that demonstrate Hympavzi's efficacy as a prophylactic treatment in this young population. The expanded label underscores efforts to address pediatric needs in areas traditionally focused on adults, thus broadening treatment options for young patients with bleeding disorders. In Europe, Chiesi's Loxujta (lomitapide) has gained EU pediatric label expansion for treating homozygous familial hypercholesterolemia, supported by strong Phase 3 data. This expansion aligns with a growing trend toward personalized medicine, tailoring treatments to specific genetic profiles even in younger populations. Collaborative efforts in biotechnology are also gaining momentum. GSK has partnered with Engitix to research liver fibrosis regression through extracellular matrix-targeted drug discovery. This collaboration highlights an industry shift towards leveraging biotechnology for innovative therapeutic solutions. Hikma Pharmaceuticals has shown confidence in the U.S. pharmaceutical manufacturing sector by committing $267 million to expand its facilities in Ohio. This expansion enhances Hikma's production capabilities while creating 350 jobs, positively impacting local economies and ensuring robust supply chain capabilities for essential medicines. The clinical trial landscape is vibrant with promising data across various therapeutic areas. Amgen's Repatha (evolocumab) has demonstrated cardiovascular risk reduction in high-risk diabetes patients without prior heart attacks or strokes, reinforcing its role not just in cholesterol management but also in broader cardiovascular risk mitigation strategies. Dexcom has made strides in metabolic diseases with its G7 continuous glucose monitor showing significant benefits for non-insulin-dependent type 2 diabetes patients. This development illustrates the increasing integration of digital health technologies into chronic disease management. Moreover, emerging treatments like Sciwind Biosciences' ecnoglutide have shown superior weight loss outcomes compared to existing therapies such as semaglutide. Such head-to-head comparisons are crucial for advancing competitive therapeutic landscapes and optimizing patient outcomes. In summary, the pharmaceutical and biotech sectors are experiencing transformative changes driven by scientific advancements and strategic collaborations. These developments not only expand treatment options across various therapeutic areas but also signify a shift toward more personalized and integrated healthcare solutions that could significantly impact patient care and drug development pathways globally. As these trends continue to evolve, they will likely drive further progressions in how pharmaceutical companies approach drug development and regulatory engagements, ultimately benefiting patients worldwide through more effective and personalized treatment modalities. Stay tuned for more updates from Pharma Daily as we continue to bring you the latest insights from the world of pharmaceuticals and biotechnology.Support the show

This Day in Legal History: Congress Repeals the Gold ClauseOn this day in 1933, Congress passed the Joint Resolution that voided the gold clauses written into nearly every long-term contract and bond obligation in the United States, both public and private. The resolution declared that any provision purporting to require payment “in gold or a particular kind of coin or currency” was “against public policy,” and that obligations could be discharged dollar for dollar in whatever legal tender currency was in force at the time of payment. It was a remarkable act of legislative power: a one-paragraph statute that rewrote the payment terms of millions of existing contracts overnight, in the middle of the Great Depression, to make Franklin Roosevelt's recent abandonment of the gold standard actually stick. The Supreme Court took up the inevitable challenge two years later in the Gold Clause Cases — Norman v. Baltimore & Ohio, Nortz v. United States, and Perry v. United States — and in February 1935 it upheld the resolution as applied to private contracts by a 5-4 vote, while telling the United States, in Perry, that it had violated its own contractual word in repudiating gold-payment promises on government bonds, but that the bondholder had suffered no compensable injury. The doctrinal residue of that compromise is still with us: Congress can use its monetary powers to alter private contract terms retroactively when monetary policy requires it, the rule that has quietly underwritten every major monetary intervention since, from Bretton Woods to the post-2008 emergency lending programs. June 5 is not a day most lawyers mark on the calendar, but the resolution Congress passed on this date is one of the cleanest examples in American law of a legislature using its enumerated powers to dissolve a contract term that had been considered, until that moment, untouchable.The Supreme Court on Thursday handed Hikma Pharmaceuticals — and the entire generic drug industry — a 9-0 win in a case that had been hanging over the so-called “skinny label” pathway for years. Justice Ketanji Brown Jackson, writing for a unanimous Court in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., held that Amarin, the maker of the brand-name fish-oil drug Vascepa, had not plausibly alleged that Hikma actively induced infringement of Amarin's patents covering a still-patented cardiovascular use of the drug. The skinny label is a feature of Hatch-Waxman generic-drug law that lets a generic manufacturer copy only the unpatented uses of a brand drug by literally carving the patented uses out of its FDA-approved label, which is supposed to let cheaper generics reach the market for the unpatented indications even while patents on other indications are still in force. Brand companies have been trying for years to sue around that carve-out under the active inducement statute, 35 U.S.C. § 271(b), by pointing to generic press releases, marketing language, or website descriptions and arguing that doctors could read those statements as encouragement to prescribe the generic for the still-patented use. The Federal Circuit had bought a version of that argument and revived Amarin's case. The Supreme Court rejected that approach, and the test that Justice Jackson articulated is meaningful: the question is not how doctors might interpret what a generic manufacturer said, but whether the manufacturer itself actively encouraged the infringing use. Neutral statements that could be read as instructions to infringe do not count. The practical effect is to shore up the skinny label pathway and make it harder for brand companies to weaponize induced infringement against generic competition. The decision was originally framed as a pharmaceutical-industry case, but its inducement standard will reach across patent law generally and into every industry where § 271(b) gets litigated.It's unanimous: SCOTUS agrees with Hikma in ‘skinny label' case vs. Amarin | Fierce PharmaAlso unanimous on Thursday: the Supreme Court in Sripetch v. SEC held that the Securities and Exchange Commission can obtain disgorgement of a wrongdoer's ill-gotten gains without having to prove that any individual investor lost money. Justice Neil Gorsuch wrote the opinion for a 9-0 Court, which is itself a small surprise given the Court's recent pattern of skepticism toward broad SEC remedial powers. The case came out of a penny-stock pump-and-dump scheme that Ongkaruck Sripetch ran across some 20 small companies — buy shares quietly, promote them aggressively, sell into the bubble — and the SEC won an order requiring him to disgorge roughly $3 million. Sripetch's argument on appeal was that disgorgement is supposed to be tied to investor harm, that the SEC had not shown specific pecuniary losses traceable to him, and that the order was therefore not the kind of equitable relief the Court approved in its 2020 Liu v. SEC decision. The Court disagreed, on traditional equity principles: disgorgement, the Court explained, is measured by the defendant's unjust gain, not the plaintiff's quantified loss, and equity has always been willing to strip a wrongdoer of profit even when the victim cannot mathematically prove harm. The practical importance for the SEC is enormous — the agency reports collecting roughly $1.4 billion in disgorgement in fiscal 2025 alone, and a contrary ruling would have forced the SEC into an evidentiary burden that pump-and-dump and insider-trading cases are notoriously bad at supplying. The opinion is also a reminder that the Court's recent administrative-state skepticism is not all in one direction: when the question is grounded in old equity doctrine, the same justices who narrowed SEC adjudication in Jarkesy are willing to leave the agency's remedial toolkit intact.US Supreme Court Backs SEC in Fight Over ‘Disgorgement' Power | US NewsThe third and most constitutionally significant of Thursday's rulings was FCC v. AT&T, in which the Supreme Court upheld 8-1 the Federal Communications Commission's longstanding practice of imposing forfeiture penalties on regulated carriers through its own in-house process, without first giving the carrier a jury trial. Chief Justice John Roberts wrote the majority, with Justice Clarence Thomas the lone dissenter. The case grew out of the FCC's headline-making fines against AT&T, Verizon, T-Mobile, and Sprint for selling access to real-time customer location data to third parties without consent — fines that ran nearly $200 million across the four carriers, with AT&T's portion at $57 million and Verizon's at $46.9 million. The carriers challenged the fines on Seventh Amendment grounds, arguing that the Court's 2024 decision in SEC v. Jarkesy — which struck down the SEC's in-house adjudication of securities-fraud penalties as a violation of the jury-trial right — should reach FCC forfeitures too. The Court said no, on a structural distinction that matters: an FCC forfeiture order is not self-executing. The FCC cannot collect on its own. If a carrier refuses to pay, the matter is referred to the Justice Department, which then has to file a civil action in federal district court — a proceeding in which the carrier is entitled to a full jury trial and the government has to prove the violation de novo, with no deference to the FCC's findings. That collection-stage jury trial, Roberts wrote, is enough to satisfy the Seventh Amendment, even though the agency itself first issues the penalty. Justice Thomas's dissent argued the in-house process is no less coercive than the SEC adjudication the Court rejected in Jarkesy and would have extended Jarkesy here. The practical takeaway: agency in-house penalty proceedings survive after Jarkesy if there is a real, downstream jury-trial backstop. Expect every regulator with a similar two-step enforcement structure to point to this opinion the next time someone tries to push Jarkesy further.Court rules against cell service providers over right to jury trial in FCC proceedings | SCOTUSblog This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

This week, This Week in Pharmacy examines several stories shaping the business, clinical, and legal future of pharmacy practice. In TWIRx News from Pharmacy Times from Megan Maroney, PharmD, BCPP, FAAPP, focused on antidepressant use, withdrawal concerns, deprescribing, and shared decision-making. The key takeaway: patients should never stop antidepressants abruptly. Pharmacists can play a vital role in reducing stigma, educating patients, and supporting safe conversations about tapering, side effects, and long-term treatment. In health technology news, FDB research presented at the 2026 AMIA Amplify Informatics Conference found that patient-specific, risk-based medication guidance reduced pharmacy alert volume by 70% in a high-volume community pharmacy setting. The model consolidates alerts into one actionable message tied to the patient's most relevant risk, helping reduce alert fatigue and improve workflow. Finally, we review a federal court ruling in Eli Lilly's lawsuit against Houston-based Empower Pharmacy over compounded tirzepatide versions of Mounjaro and Zepbound. The judge dismissed key federal trademark and Texas unfair competition claims, while allowing other state claims to continue. Andy Crawford, with Keysource is back on TWIRx talking about the U.S. Supreme Court taking up Hikma Pharmaceuticals USA Inc. v. Amarin Pharma Inc., a case that could significantly affect generic drug competition. At issue is whether Hikma's marketing materials and public communications around its generic version of Amarin's fish oil-based cardiovascular drug improperly promoted a still-patented use. Hikma and the broader generic industry argue the case is about protecting “skinny label” rules, which allow generics to carve out patented indications while still bringing lower-cost medications to market. For pharmacists, the decision could influence generic availability, substitution confidence, pricing pressure, and how manufacturers communicate with providers and pharmacies. Thanks to our sponsors, CassianRx and IPC, for supporting independent pharmacy, innovation, and the future of patient-centered care.

A case in which the Court will decide (1) when a generic drug manufacturer excludes a patented use from its label, whether it still be liable for inducing infringement if it calls its product a “generic version” of the brand-name drug and cites publicly available information about the brand-name drug's sales; and (2) whether a patent infringement complaint can survive dismissal if it does not allege that the defendant made any statement specifically instructing or encouraging the patented use.

Administrative Law: When a generic drug label fully carves out a patented use, are allegations that the generic drugmaker calls its product a "generic version" and cites public information about the branded drug enough to plead induced infringement of the patented use? - Argued: Wed, 29 Apr 2026 13:44:54 EDT

Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. | 04/29/26 | Docket #: 24-889 24-889 HIKMA PHARMACEUTICALS V. AMARIN PHARMA, INC. DECISION BELOW: 104 F.4th 1370 CERT. GRANTED 1/16/2026 QUESTION PRESENTED: Congress passed the Hatch-Waxman Act "[t]o facilitate the approval of generic drugs as soon as patents allow." Caraco Pharm. Labs., Ltd. v. Novo Nordisk A/S , 566 U.S. 399, 405 (2012). Recognizing that many drugs are approved for both patented and unpatented uses, Congress sought to ensure "that one patented use will not foreclose marketing a generic drug for other unpatented ones." Id . at 415. The statutory mechanism is a "skinny label": Generic drugmakers "carve out" patented uses from their labels, leaving only instructions to use generic drugs for their unpatented uses. See 21 U.S.C. § 355(j)(2)(A)(viii). Congress designed this carve-out mechanism to encourage competition and to protect generic drugmakers from allegations that marketing a generic drug for an unpatented use "actively induces infringement." 35 U.S.C. § 271(b). After all, active inducement requires "clear expression or other affirmative steps taken to foster infringement"-there is no "liability when a defendant merely sells a commercial product suitable for some lawful use." Metro-Goldwyn- Mayer Studios Inc. v. Grokster, Ltd. , 545 U.S. 913, 936-937 & n.11 (2005). The questions presented are: 1. When a generic drug label fully carves out a patented use, are allegations that the generic drugmaker calls its product a "generic version" and cites public information about the branded drug (e.g., sales) enough to plead induced infringement of the patented use? 2. Does a complaint state a claim for induced infringement of a patented method if it does not allege any instruction or other statement by the defendant that encourages, or even mentions, the patented use? LOWER COURT CASE NUMBER: 2023-1169

Episode 230: Les communs (en matière foncière) en Tunisie à l'époque moderne : à l'épreuve des normes en vigueur et des stratégies des acteurs sociaux L'essentiel des écrits sur les questions foncières en Tunisie, mais aussi dans tout le reste du Maghreb, est le produit du savoir colonial. Ce dernier a fondé toute une manière de voir des réalités totalement en faveur d'une politique de spoliation des terres au profit des colons. D'où la nécessité de réviser ce savoir et surtout de l'indigéniser en le déconstruisant totalement si l'on veut réellement se libérer de ce fardeau handicapant. La question de l'appropriation des mawât ne devient constamment posée que durant la période précoloniale (16e – 19esiècles). A l'époque hafside, c'est-à-dire avant l'installation du pouvoir turc en 1574, la gestion des terres mawât se faisait, selon la norme islamique. L'action de leur vivification est soumise à l'autorisation préalable du Bayt al-mâl si la terre mawât en question est située dans la zone occupée (al-‘amara), moyennant le paiement d'une taxe de vivification. En revanche, si la terre mawât se trouve loin de la zone occupée, l'action de vivification n'exige aucune autorisation préalable. Elle est soumise, quand même, au paiement d'une taxe de vivification. C'est à partir de l'époque ottomane, en 1574, que la gestion des terres mawât commence réellement à faire objet de débats, sans cesse renouvelés, entre les différents protagonistes, et ce jusqu'à la veille de la colonisation en 1881. Avec la colonisation, leur gestion prend d'autres dimensions encore plus sophistiquées, justement pour satisfaire à la demande de la colonie française installée en Tunisie.  Abdelhamid Henia est Professeur émérite de l'Université de Tunis, fondateur et ancien Directeur du Laboratoire ‘‘DIRASET'' études maghrébines, ancien Directeur du Département d'histoire à Doha Institute For Graduate Studies, membre de l'Académie tunisienne des sciences, des lettres et des arts - « Beit al-Hikma », et Président du Département des sciences humaines et sociales dans cette même institution. Il a publié de nombreux ouvrages : Le Jérid : ses rapports avec le Beylik de Tunis (1676-1840) (1980), Propriété et stratégies sociales à Tunis (XVIe-XIXe siècles) (1999), La recherche au Laboratoire DIRASET études maghrébines sur la base de l'interdisciplinarité et de la diversité des méthodes : pour une indigénisation de la recherche (en arabe) (2012), Le frère, le sujet et le citoyen. Dynamique du statut politique de l'individu en Tunisie (2015), et La Tunisie ottomane. Construction de l'Etat et du territoire (en arabe : Tûnis al-‘uthmâniyya. Binâ' al-dawla wa-l-majâl) (2024). Il a coordonné et publié onze ouvrages collectifs, et il a quatre-vingts articles publiés en arabe, en français et en italien. Ses recherches ont porté principalement sur les aspects de la modernité en Tunisie et au Maghreb en général, sur le processus de leur construction, notamment celui de l'État moderne, le rapport entre le religieux et le politique, le processus d'individuation de la société et la question de l'indigénisation du savoir. Ce podcast a été enregistré via Zoom le 29 mai 2025 et s'inscrit dans le cadre du programme « Le Maghreb vu des périphéries : Conflit et coopération autour des communs » soutenu par le CAORC et Carnegie Corporation of New York et réalisé par le CEMA et le CEMAT. Nous remercions Bacem Affès, compositeur de musique et soliste de oud, pour son interprétation de « Isteftah » dans l'introduction et la conclusion de ce podcast. Production et montage : Lena Krause, AIMS Development and Digital Resources Liaison.

The Supreme Court is set to hear Hikma v. Amarin, a battle over drug patents that could raise costs for patients and change the way generic companies do business. Guests:Hans Sauer, adjunct professor, Georgetown Law; former vice president of intellectual property, Biotechnology Innovation OrganizationSean Tu, professor of law, University of AlabamaDennies Varughese, partner; Sterne, Kessler, Goldstein and FoxLeslie Walker, senior reporter, TradeoffsLearn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift. Hosted on Acast. See acast.com/privacy for more information.

Is it fair that investors earn more than workers? In Episode 286, we tackle a listener comment that sparked a real debate about capitalism, wages, and the power of ownership. We also cover the latest dividend hikes from American Express (+16%), Munich RE (+20%), and the Cheesecake Factory (+11%), share thoughts on the new L&G Global Quality Dividend ETF, and answer questions on Petrobras, Frontline, T. Rowe Price, and more. Topics covered: Why dividend growth often outpaces salary increasesTexas Instruments & Nvidia humanoid robot collaborationL&G Global Quality Dividend ETF breakdownUsing AI tools in investment researchListener Q&A: Petrobras, Frontline, HIKMA, T. Rowe Price, BRAVIDIA & moreJoin us :[Facebook]  Https://www.facebook.com/groups/dividendtalk[Twitter] -   @DividendTalk_    , @European_DG[Discord] - https://discord.gg/nJyt9KWAB5[Newsletter] - https://dividendtalk.eu/download-your-free-samples/

My co-host Ken Suzan and I are welcoming you to episode 171 of our podcast IP Fridays! Today's interview guest is the president of the German Patent and Trademark Office Eva Schewior! But before we jump into this very interesting interview, I have news for you: The US Supreme Court has taken up an important patent law case concerning so-called “skinny labels” for generic drugs. Specifically, the highest US court is reviewing a case in which Amarin accuses generic drug manufacturer Hikma of inciting doctors to use the cholesterol drug Vascepa in violation of patents by providing a limited package insert. In two landmark decisions, the UPC Court of Appeal clarified the criteria for inventive step and essentially confirmed the EPO’s typical “problem-solution” approach (Amgen v Sanofi and Meril v Edwards). However, experts are not entirely sure whether the Court of Appeal’s decisions, particularly those relating to the determination of the closest prior art, deviate from EPO practice. As a result of Brexit, mutual recognition of trademark use between the EU and the UK will cease to apply from January 1, 2026. Use of a trademark only in the UK will then no longer count as use of an EU trademark for the purpose of maintaining rights – and conversely, EU use will no longer count for British trademarks. Bayer is attacking several mRNA vaccine manufacturers in the US (Pfizer, BioNTech, Moderna, and J&J separately). The core allegation: patent infringements relating to old (Monsanto) patents on mRNA stabilization; Bayer is seeking damages, not sales bans. DISCO Pharmaceuticals from Cologne signs an exclusive license agreement with Amgen (potentially up to USD 618 million plus royalties) for novel cancer therapies targeting surface structures. Relevant from an IP perspective: license scope, milestones, data/know-how allocation. And now let's jump into the interview with Eva Schewior! The German IP System in Transition: Key Insights from DPMA President Eva Schewior In an in-depth conversation on the IP Fridays podcast, Eva Schewior, President of the German Patent and Trademark Office (DPMA), outlined how Germany's IP system is responding to rising demand, technological change, and a fundamentally altered European patent landscape. The interview offers valuable insights for innovators, companies, and IP professionals navigating patent, trademark, and design protection in Europe. Sustained Demand and Procedural Efficiency Despite the introduction of the Unitary Patent system, national German IP rights continue to see strong and growing demand. According to Schewior, application numbers at the DPMA have been increasing for years, which she views as a strong vote of confidence in the quality and reliability of German IP rights. At the same time, this success creates pressure on examination capacity. The average duration of patent proceedings at the DPMA is currently around three years and two months from filing to grant, provided applicants request examination early and avoid extensions. Internationally, this timeframe remains competitive. Nevertheless, shortening procedures remains a strategic priority. Search requests alone have risen by almost 50% over the past decade, yet the DPMA still delivers search reports on time in around 90% of cases. To better reflect applicant needs, the DPMA distinguishes between two main user groups: applicants seeking a rapid grant, often as a basis for international filings, and applicants primarily interested in a fast, high-quality initial assessment through search or first examination. Future procedural adjustments are being considered to better serve both groups. The Role of Artificial Intelligence Artificial intelligence already plays a practical role at the DPMA, particularly in patent search, classification, and the translation of Asian patent literature. Schewior emphasized that the office is closely monitoring rapid developments in AI to assess where these tools can further improve efficiency. However, she made clear that AI will remain a supporting technology. In public administration, and especially in IP examination, final decisions must always be taken and reviewed by humans. AI is seen as a way to relieve examiners of routine tasks so they can focus on substantive examination and quality. Maintaining and Monitoring Examination Quality Quality assurance is a central pillar of the DPMA's work. Schewior reported consistently positive feedback from users, but stressed that maintaining quality is a continuous task. The office applies systematic double checks for grants and refusals and uses internal quality management tools to randomly review searches and first office actions during ongoing proceedings. External feedback is equally important. The DPMA's User Advisory Board, which includes patent attorneys, startups, and patent information centers, plays a key role in identifying issues and suggesting improvements. Several of its recommendations have already been implemented. Trademark Filings and Bad-Faith Applications The trademark side of the DPMA has experienced particularly strong growth. In 2025, the office received around 95,000 trademark applications, an increase of approximately 18% compared to the previous year. Much of this growth came from abroad, especially from China. While new trademark types such as sound marks, multimedia marks, and holograms have so far seen only moderate uptake, word marks and figurative marks remain dominant. A growing challenge, however, is the rise in bad-faith trademark filings. The DPMA has responded by intensively training examiners to identify and handle such cases. Procedural reforms following EU trademark law modernization have also shifted competencies. Applicants can now choose whether to bring revocation and invalidity actions before the courts or directly before the DPMA. While courts may act faster, proceedings before the DPMA involve significantly lower financial risk, as each party generally bears its own costs. Accelerated Examination as a Practical Tool Despite rising filing numbers, the DPMA aims to avoid significant delays in trademark proceedings. Organizational restructuring within the trademark department is intended to balance workloads across teams. Schewior highlighted the option of accelerated trademark examination, available for a relatively modest additional fee. In practice, this can lead to registration within a matter of weeks, without affecting priority, since the filing date remains decisive. New Protection for Geographical Indications A major recent development is the extension of EU-wide protection for geographical indications to craft and industrial products. Since late 2025, the DPMA acts as the national authority for German applications in this area. The first application has already been filed, notably for a traditional German product. Under the new system, applications undergo a national examination phase at the DPMA before being forwarded to the EUIPO for final decision. Products eligible for protection must originate from a specific region and derive their quality or reputation from that origin, with at least one production step taking place there. The EU estimates that around 40 German products may qualify. Outreach, SMEs, and Education Schewior underlined the DPMA's statutory duty to inform the public about IP rights, with a particular focus on small and medium-sized enterprises. The office has significantly expanded its presence on platforms such as LinkedIn and YouTube, offering accessible and practical IP content. Studies show that fewer than 10% of European SMEs use IP rights, despite evidence that IP-owning companies generate higher revenues. To address this gap, the DPMA is expanding outreach formats, strengthening cooperation with educational institutions, and publishing new empirical studies, including a forthcoming analysis of patenting behavior among innovative German startups conducted with WIPO. Strategic Challenges Ahead Looking forward, Schewior identified several key challenges: insufficient awareness of IP protection among SMEs and startups, a tendency in some sectors to rely solely on trade secrets, and the growing problem of product and trademark piracy linked to organized crime. From an institutional perspective, the DPMA must remain attractive and competitive in a European system offering multiple routes to protection. This requires legally robust decisions, efficient procedures, qualified staff, and continuous investment in IT and training. Careers at the DPMA Finally, Schewior highlighted recruitment as a strategic priority. The DPMA recently hired around 50 new patent examiners and continues to seek experts in fields such as electrical engineering, e-mobility, IT, and aerospace, as well as IT specialists, lawyers, and staff in many other functions. She emphasized the DPMA's role as Europe's largest national patent office and a globally significant, stable, and family-friendly employer at the forefront of technological development. German and European Patents as Complementary Options In her closing remarks, Schewior addressed the post-UPC patent landscape. Rather than competing, German and European patent systems complement each other. For many SMEs, a German patent alone may be sufficient, particularly where Germany is the core market. At the same time, the possibility of holding both a European patent and a national German patent offers strategic resilience, as national protection can survive even if a European patent is revoked. Her key message was clear: the range of options has never been broader, but making informed strategic choices is more important than ever. If you would like, I can also adapt this article for a specialist legal audience, condense it for a magazine format, or rework it as a thought-leadership piece for LinkedIn or your website. Rolf Claessen: Today's interview guest is Eva Schewior. If you don't know her yet, she is the President of the German Patent and Trademark Office. Thank you very much for being here. Eva Schewior: I'm very happy that you're having me today. Thank you, Mr. Claessen. Rolf Claessen: Shortening the length of procedures has been a stated goal since you took office. What is the current situation, and which measures are in place to achieve this goal? Eva Schewior: First of all, I'm very glad that German IP rights are in high demand. Even though applicants in Europe have multiple options today to obtain protection for their innovations, we have seen increasing application numbers for years at my office, even after the introduction of the Unitary Patent system. I see this as very positive feedback for our work. It is clear, however, that the high number of applications leads to a constantly increasing workload. At the same time, we want to remain attractive for our applicants. This means we must offer not only high-quality IP rights but also reasonable durations of proceedings. Ensuring this remains a central and permanent objective of our strategy. The average duration of proceedings from filing to grant is currently about three years and two months, provided that applicants file an examination request within the first four months after application and do not request extensions of time limits. In other cases, the average duration of proceedings is admittedly longer. With these three years and two months, we do not have to shy away from international comparison. Nonetheless, we strive to get better. In the last few years, we were able to improve the number of concluded proceedings or to keep them at a high level. In some areas, we were even able to shorten durations of proceedings a bit, though not yet to the extent that we would have wished for. Our efforts are often overtaken by the increasing demand for our services. Just to give you an example, in the last ten to fifteen years, search requests increased by nearly fifty percent. Despite this, we managed to deliver search reports in ninety percent of all cases in time, so that customers have enough time left to take a decision on a subsequent application. I have to admit that we are not equally successful with the first official communication containing the first results of our examination. Here, our applicants need a bit more patience due to longer durations of proceedings. But I think I do not have to explain to your expert audience that longer processing times depend on various reasons, which are in no way solely to be found on our side as an examination office. To further reduce the length of proceedings, we need targeted measures. To identify them, we have analyzed the needs of our applicants. It has been shown that there are two main interests in patent procedures. About three quarters of our applicants have a very strong interest in obtaining a patent. They mainly expect us to make fast decisions on their applications. Here we find applicants who want to have their invention protected within Germany but often also wish for subsequent protection outside Germany. The remaining quarter consists of applicants that are solely interested in a fast and high-quality first assessment of the application by means of a search or a first official examination. We observe that these applicants use our services before they subsequently apply outside Germany. This latter group has little interest in continuing the procedure before my office here in Germany. We are currently considering how we can act in the best interest of both groups. What I can certainly say is that we will continue to address this topic. And of course, in general, it can be said that if we want to shorten the duration of proceedings, we need motivated and highly skilled patent examiners. Therefore, we are currently recruiting many young colleagues for our offices in Munich and Jena, and we want to make our procedures more efficient by using new technical options, thus taking workload from patent examiners and enabling them to concentrate on their core tasks and on speedy examination. Rolf Claessen: Thank you very much. I also feel that the German Patent and Trademark Office has become quite popular, especially with the start of the UPC. Some applicants seem to find that it is a very clever option to also file national patents in Germany. Eva Schewior: I think you're perfectly right, and I think we will come to this point later. Rolf Claessen: In 2023, you mentioned artificial intelligence as an important tool for supporting patent examiners. What has happened regarding AI since then? Eva Schewior: Of course, we are already successfully using AI at our office. For instance, in the field of patent search, we use AI-based tools that make our examiners' work easier. We also use AI quite successfully for classification and for the translation of Asian patent literature into English. In the meantime, we have seen a rapid development of AI in the market. I think it is strategically imperative to get an overview and to make realistic assessments of what AI is capable of doing to make our procedures more efficient. Therefore, we are observing the market to find out where AI can perform tasks so that we enable examiners to concentrate on their core business. There are many ideas right now in our office where artificial intelligence can help us tackle challenges, for instance demographic change, which certainly also affects our office, and maintaining our quality standards. We will strategically promote new tools in this field to cope with these challenges. But this much is also clear: humans will always stay in our focus. Especially in public administration, I consider it a fundamental principle that in the end, decisions must be taken and reviewed by humans. AI may help us reach our goals in a more efficient way, but it can never replace patent or trademark examiners. Rolf Claessen: You have made quality improvements in patent examination a priority and have already implemented a number of measures. How would you describe the current situation? Eva Schewior: I often receive positive feedback from different sides that our users are very satisfied with the quality of our examination, and I'm very glad about that. But maintaining this quality standard is a permanent task, and we must not become careless here. For years, for instance, we have established double checks for all grants and rejections. In addition, we have introduced a quality management tool that enables us, even during the examination process, to randomly check the quality of first office communications and searches. This helps us detect critical trends and take appropriate countermeasures at a very early stage. What is also very important when it comes to patent quality is to actively ask our customers for their feedback. We do this in different ways. Just to give you an example, we have a User Advisory Board, which is a panel of external experts implemented a couple of years ago. Discussing questions of quality is regularly on the agenda of this board. We carefully listen to criticism, ideas, and suggestions, and we have already implemented some of them for the benefit of the office and our users. Rolf Claessen: The German Patent and Trademark Office, as the largest patent and trademark office in Europe, records very high numbers of trademark applications. What are you currently especially concerned with in the trademark area? Eva Schewior: In 2025, we saw around ninety-five thousand trademark applications. This is an increase of eighteen percent compared to the previous year, and I have to say that this took us by surprise. Especially applications from outside Germany, and above all from China, have risen significantly. It is of course challenging to cope with such a sudden increase on an organizational level. Another challenge is dealing with trademark applications filed in bad faith, which we are currently seeing more and more of. We have thoroughly trained our trademark examiners on how to identify and handle such applications. As regards the new types of trademarks, the rush has been moderate so far. Sound marks, multimedia marks, or holograms are apparently not yet common solutions for the majority of applicants. The key focus remains on word marks and combined word and figurative marks. Nevertheless, I believe that the new trademark types are a meaningful supplement and may play a greater role as digitization advances. The most significant changes, however, concern procedures. Applicants can now choose whether to file revocation or invalidity actions with the courts or with our office. While courts may proceed somewhat faster, the financial risk is higher. Before the DPMA, each party generally bears its own costs, apart from exceptional cases. Rolf Claessen: How does this dynamic filing development impact the duration of trademark proceedings? Eva Schewior: This is indeed a major organizational challenge. For a long time, our trademark department managed to keep durations of proceedings very short, especially with regard to registration. Despite the recent increases in applications, especially in 2025, we hope to avoid a significant extension of processing times. We have restructured the organization of the trademark department to distribute applications more equally among teams. Applicants should also be aware that it is possible to request accelerated examination for a relatively moderate fee of two hundred euros. This often leads to registration within a very short time. The filing date, of course, always determines priority. Rolf Claessen: Since December 2025, the EU grants protection not only for agricultural products but also for craft and industrial products through geographical indications. Has your office already received applications? Eva Schewior: Yes, we have received our first application, and interestingly it concerns garden gnomes. Protected geographical indications are an important topic because they help maintain traditional know-how in regions and secure local jobs. The DPMA is the competent authority for Germany. Applications go through a national examination phase at our office before being forwarded to the EUIPO, which takes the final decision on EU-wide registration. Eligible products must originate from a specific region and derive their quality, reputation, or characteristics from that origin, with at least one production step taking place there. Rolf Claessen: The DPMA has expanded its outreach activities, including social media. What else is planned? Eva Schewior: Raising awareness of IP rights, especially among small and medium-sized enterprises, is part of our statutory duty. We currently use LinkedIn and YouTube to communicate IP topics in an understandable and engaging way. We also plan dedicated LinkedIn channels, for example for SMEs. Studies show that fewer than ten percent of European SMEs use IP rights, even though those that do earn significantly more on average. In 2026, we will further expand outreach activities, cooperate more closely with universities and educational institutions, and publish new studies, including one on the patenting behavior of innovative German start-ups conducted together with WIPO. Rolf Claessen: Where do you see the biggest future challenges in IP? Eva Schewior: Germany depends on innovation, but awareness of IP protection is still insufficient, particularly among SMEs and start-ups. Some companies deliberately avoid IP rights and rely on trade secrets, which I consider risky. Another growing concern is the increase in product and trademark piracy, often linked to organized crime. For our office, remaining attractive and competitive is crucial. Applicants have many options in Europe, so we need fast procedures, legally robust decisions, qualified staff, and modern IT systems. Rolf Claessen: The DPMA is currently recruiting. Which areas are you focusing on? Eva Schewior: Our focus is on patent examination and IT. We recently hired fifty new patent examiners and are particularly looking for experts in fields such as electrical engineering, e-mobility, IT, and aerospace. We are Europe's largest national patent office and offer meaningful, secure jobs with fair compensation and strong development opportunities. Rolf Claessen: Is there a final message you would like to share with our listeners? Eva Schewior: The Unitary Patent system has created many new options. German and European patent systems do not compete; they complement each other. For many SMEs, a German patent may already be sufficient, especially where Germany is the core market. Holding both European and national patents can also be a strategic advantage. My key message is: be aware of the options, stay informed, and choose your IP strategy deliberately. Rolf Claessen: Thank you very much for being on IP Fridays. Eva Schewior: Thank you for having me. It was a pleasure.

Keine Ausreden mehr! - Auch dein schlafendes Herz kann erwachen I Teil 13 I Hikma 44 I Hikem-i Ataiyye von Ibn Ataullah el- Iskenderi

Generics, which make up approximately 90% of prescription volume in the U.S., are produced primarily in India as Hikma looks to onshore production of these critical drugs. Greg Slabodkin Read by Brittany Duncan  https://www.pharmamanufacturing.com/all-articles/article/55302441/hikmas-planned-1b-us-investment-comes-at-critical-time-for-generic-medicines-supply 

Mit wem du gehst, bestimmt wohin du gehst I Teil 12 I Hikma 41 I Hikem-i Ataiyye von Ibn Ataullah el- Iskenderi

Wer bist du, wenn niemand zuschaut? - Das ist dein wahres "Ich"! I Hikma 11 I Hikem-i Ataiyye von Ibn Ataullah el- Iskenderi

Allah Ta'ala is referred to as “The First Beloved” - meaning love for Him comes first. What is the reason for this? Why is love for Allah stronger than love for anyone else? And why is it the first love?What has the Imam explained regarding this in the Ikhwan us Safa? What makes love for Allah truly right and valid? What is the pinnacle of sincerity in love?Syedna Taher Fakhruddin TUS answers these questions in this Majlis, the 82nd in the Majalis al Hikma series.Watch in English: https://youtu.be/5sRoxsV5vy4Watch in Dawat ni Zabaan: https://youtu.be/NK_zw-IaWecWatch in Arabic: https://youtu.be/fuCExZigYE8Questions can be asked by email to info@fatemidawat.com

Gebet oder Schauspiel? I Hikma 10 I Hikem-i Ataiyye von Ibn Ataullah el- Iskenderi

Dawat ni Zabaan ma dekho: https://youtu.be/NK_zw-IaWecKhuda Ta'ala ne “Ma'shuqe Awwal” kahyu - yaani ke sagla si pehla mohabbat Khuda waaste. Ehno su sabab che? Sagla karta Khuda ni mohabbat ziyada, em sukaam?Ikhwan us Safa ma Imam ye su farmayu che? Haqiqat ma Khuda ni mohabbat kai raah par saheeh thaai? Mohabbat ma ikhlaas ni zirwat su che?Majalis al Hikma ni 82 mi Majlis ma Syedna Taher Fakhruddin TUS aa suaalo na jawaab farmawe chhe.Je Mumineen ne koi suaal hoi te info@fatemidawat.com na zaree'a si poochi sake chhe.This Majlis will also be available in English and available in Arabic soon, insha'Allah.

Was deine Taten über dein Herz verraten I Hikma 9 I Hikem-i Ataiyye von Ibn Ataullah el- Iskenderi

Wenn Allah (cc) das Herz für die Ma'rifa öffnet I Hikma 8 I Hikem-i Ataiyye von Ibn Ataullah el- Iskenderi

Vom Zweifel zur Gewissenheit I Die Reise des Herzens I Hikma 7 I Hikem-i Ataiyye von Ibn Ataullah el- Iskenderi

Die verborgene Weisheit hinter der Erhörung deiner Du'a I Hikma 6 I Hikem-i Ataiyye von Ibn Ataullah el- Iskenderi

Die Blindheit des Herzens I Hikma 5 I Hikem-i Ataiyye von Ibn Ataullah el- Iskenderi

Those who believe in God are many, they worship God in many different ways and do good deeds. But the reward is attained only if God accepts the deeds. What makes deeds accepted by God? Why is walayat - the recognition of and allegiance to God's chosen ones - so central - so much so that the acceptance of all deeds is subject to walayat? Why is salvation linked to walayat? How is walayat connected with obedience? What does the Quran Majeed, the Prophet, and our guides tell us about walayat?Syedna TUS answers these questions in this Majlis, the 81st in the Majalis al Hikma series.Watch in English: https://youtu.be/kA4ROHMHcuIWatch in Dawat ni Zabaan: https://youtu.be/TM_2BrarmbkWatch in Arabic: https://youtu.be/IGkawwuw-P0Questions can be asked by email to info@fatemidawat.com

Ghana logo khuda ma maane che, ane khuda ni bandagi kare che, garche alag alag reet si, ane ye achha amal bhi karta hase. Magar, khuda amal qabool kare toj amal nu sawab mile. Kehna sabab khuda amal qabool kare che? Walayat ehwi su cheez che ke bija sagla amal nu qabooliyyat walayat saathe jorayu huwu che? Sukaam walayat na hoi toh koi bhi amal na ginai? Najaat sukaam walayat na sabab aj che? Walayat kiwi reet si ta'at saathe joraayu che? Qur'an Majeed, Rasulullah, ane apna Awliyaa' walayat na baara ma su zikr kare che?Majalis al Hikma ni 81 mi Majlis ma Syedna Taher Fakhruddin TUS aa suaalo na jawaab farmawe chhe.Dawat ni Zabaan ma dekho: https://youtu.be/TM_2BrarmbkEnglish ma dekho: https://youtu.be/kA4ROHMHcuIArabi ma dekho: https://youtu.be/IGkawwuw-P0Je Mumineen ne koi suaal hoi te info@fatemidawat.com na zaree'a si poochi sake chhe.

Die Weißheit des Vertrauens I Hikma 4 I Hikem-i Ataiyye von Ibn Ataullah el- Iskenderi

In deze podcast bepreekt Koos van der Hoeven met Hans Severens over de vraag of de inzet van nieuwe geneesmiddelen en technologieën tot verdringingseffecten in de zorg leidt. Aan bod komen onder andere de marginale waarde van ziekenhuiszorg berekend uit een kwantitatief onderzoek van ZiN, een kwalitatief onderzoek onder een aantal stakeholders, en de begrippen incremental cost-effectiveness ratio (ICER) en quality adjusted life year (QALY).Referenties 1. Voortgangsbrief pakketbeheer van dure geneesmiddelen, d.d. 11 april 2024. Te raadplegen via: https://open.overheid.nl/documenten/40749f67-692d-44be-9cc7-16f7ede55aa0/file. 2. Adang E, et al. Verdringingseffecten binnen het Nederlandse zorgstelsel. November 2018. Te raadplegen via: https://www.zorginstituutnederland.nl/publicaties/publicatie/2018/04/17/verdringing-binnen-de-ziekenhuiszorg.Disclosures Dr. Hans Severens: Alexion, Amgen, AstraZeneca, Boehringer-Ingelheim, Daiichi Sankyo, Gilead, GSK, Hikma, Idorsia, MSD, Nova Nordisk, Pierre Fabre, Recor Medical, Sanofi, Takeda. Prof. dr. ir. Koos van der Hoeven: Astellas, Bayer, BMS, Daiichi Sankyo, Gilead, Novartis, Pfizer, Seagen, voorzitter Oncomid, lid Adviescollege VIG en lid RVT DICA.Deze podcast wordt u aangeboden door Gilead Sciences.NL-UNB-0796

The topics, stocks and shares mentions / discussed include: Could this stock become a future 1000% winner Animalcare Group / ANCR Genus / GNS Hikma Pharma / HIK Exelixis / EXEL Venture Life Group / VLG Polar Capital Healthcare Opportunities Fund Invesco S&P Smallcap Healthcare ETF Uniphar / UPR Novacyt / NCYT Deltic Energy / DELT Totally / TLY July's TwinPetesInvesting Challenge winner Pharma / Biotech / Healthcare Dividends FTSE 100 / FTSE All-Share / AIM All-share Podcast ambassadors Charity Sharescope / Sharepad special discount offer code ShareScope | SharePad : TwinPetes Phil Oakley's blog Investingstuff | Phil Oakley | Substack Henry Viola-Heir's blog Home – The Ethical Entrepreneur Investors' Chronicle sponsor Special Trial Offers (investorschronicle.co.uk) the TwinPetesInvesting Challenge Harriman House books Harriman House – Independently minded publishing Powder Monkey Brewing Co All Products – Powder Monkey Brewing Co 10% discount code : TWINPETES CENTREPOINT Charity Appeal please make a donation on the TwinPetes Investing Charity Challenge 2024 Henry Viola-Heir is fundraising for Centrepoint (justgiving.com) Just Giving page Investing Trading & more The Twin Petes Challenge 2024 / Charity fundraise is for the CENTREPOINT Charity. Have you enjoyed one or more of these podcasts. Yes . Then please make a donation , every pound will help.  Henry Viola-Heir is fundraising for Centrepoint (justgiving.com)  JUST GIVING TWIN PETES FUNDRAISING FOR THE CENTREPOINT Henry Viola-Heir is fundraising for Centrepoint (justgiving.com) Thank you. The Twin Petes Investing podcasts will be linked to and written about on the Conkers3 website and also on available via your favourite podcast and social media platforms. Thank you for reading this article and listening to this podcast, we hope you enjoyed it. Please share this article with others that you know will find it of interest.  PLEASE SUBSCRIBE TO THE TWIN PETES INVESTING PLATFORM THAT YOU ARE LISTENING TO THIS PODCAST ON. THANK YOU.

Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc.

The Ras al-Hikma peninsula on the north coast of Egypt is going to become a new city. But it's going to be built and managed by another country, the United Arab Emirates. In a deal signed earlier this year, Egypt gave the UAE the right to develop this 170 square kilometre area in return for $35 billion dollars. The Egyptian economy was in a critical position, and needed a quick cash injection to get it out of trouble, and the Ras al-Hikma deal was seen as the solution. But it is a very unusual deal. Both because of the amount of money involved, but also because it gives another country the right to essentially build and own a city in Egypt. And it's not known whether it provides a long-term solution to Egypt's economic problems. Presenter: Mpho Lakaje Guests: Wael Gamal, from ‘The Egyptian Initiative for Personal Rights' a human rights think tank based in Cairo, Yomn Hamaky an Economics Professor at Ain Shams university in Egypt, and Ahmed, Professor of Economics at Cairo University.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Denali, a biotech company, received a $500 million investment after facing setbacks in a clinical trial for an ALS drug. Viking presented data suggesting their obesity drug could rival those from Eli Lilly and Novo Nordisk. Janux's shares tripled after positive results for their cancer immunotherapy drug. Minerva's schizophrenia drug was rejected by the FDA.Transitioning to the next news, Viking Therapeutics achieved a significant milestone in their obesity drug development with positive results from a Phase II study showing patients losing up to nearly 15% of their weight in three months. However, Minerva Neurosciences faced a setback as their schizophrenia treatment candidate was rejected by the FDA due to lack of data and other factors. Moving on, Denali Therapeutics secured $500 million in financing, Biomarin Pharmaceuticals received a subpoena from the Department of Justice, and Merck's drug Bridion could face generic competition from Hikma. Novo Nordisk also signed a potential $1.46 billion deal with Neomorph for their molecular glue platform. Additionally, Janux's stock soared after positive results from two candidates in Phase I trials. Biopharma companies like Denali, Galapagos, and Adaptive have announced layoffs as part of their restructuring efforts.The article also discusses trends in obesity drug treatments and strategies for improving engagement with healthcare professionals using AI-powered data. Additionally, the article highlights upcoming webinars on omnichannel HCP engagement and filling roles in life sciences. Biopharma Dive provides news and insights on the biotech and pharma industry, covering topics like clinical trials, FDA approvals, gene therapy, drug pricing, and research partnerships.

Join our host, Evren Ozkaya, as he welcomes Faris Hattar, Associate Director of Supply Chain Operations at Hikma Saudi Arabia, for an insightful discussion on effectively managing cost pressures in generic drug manufacturing. In this episode, they delve into the challenges faced by pharmaceutical leaders, addressing issues such as high transportation costs, over reliance on a few offshore suppliers and manufacturing bottlenecks. Faris shares strategies to overcome these challenges, emphasizing the importance of enhancing visibility in factories and supply chains to enable swift and informed decision-making. Later in the conversation, Evren and his guest explore the current level of digitalization in the pharmaceutical industry and the underlying reasons for its status.

APAC stocks were mostly positive amid tailwinds from the tech uplift in US futures following NVIDIA earnings.NVIDIA surged by over 9% after-hours after beating on top and bottom lines and offering strong sales guidance.FOMC minutes proved to be a non-event and echoed the broader tone of Fed speak seen in the wake of the January meeting.European equity futures indicate a higher open with Euro Stoxx 50 future +0.8% after the cash market closed up 0.3% on Wednesday.DXY is back below the 104 level, NZD continues to climb and USD/JPY holds onto 150 status.Looking ahead, highlights include EZ, UK & US PMIs, EZ CPI (Final), US IJC, ECB Minutes, CBRT Policy Announcement, Speeches from Fed's Jefferson, Bowman, Harker, Kashkari & Cook, Supply from US.Earnings from Lloyds, Anglo American, WPP, Hays, Hikma, Rolls Royce, Axa, Engie, Heidelberg Materials, Mercedes Benz, Hochtief, Nestle, Zurich Insurance, BE Semiconductor, Telefonica, Iberdrola, Repsol, Pioneer Natural Resources, Moderna, Intuit & Booking.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Talking Teeth With Dr. Anas Aloum, Hikma Medical Center Hikma Medical Center has over 40 years legacy of offering safe and efficient dental care in Abu Dhabi. Dr. Anas

Mariah and Hikma are back so you know it must mean we're talking about the latest season of Love is Blind. But we begin by talking about the end of the WGA after 148 days on strike. Follow us on Instagram and on Twitter.

Sîratu'n Nabî - 05 "Hikma bi nekk ci jànga Sîra Yonent bi SHW". Ci kàddug Sëriñ Basiiru MBÀKKE Abdu Kariim --- Send in a voice message: https://podcasters.spotify.com/pod/show/librairie-majalis/message

A deep dive into key themes we've been focusing on, recent additions to the portfolio, and a few changes.   Highlights: Quick recap: What has changed with the portfolio since 2022? What we mean by “engaged owners” (and the difference they can make) Why we are looking for companies with lower duration How we try to find a variant perception from the market—and some examples Recent additions to the portfolio: Dermapharm, Donnelley Financial, Hikma, Ipsos, SoftwareONE, and Technogym Our new approach to the reverse roadshow process

Hashem meets up with Shereen Al-Mulla, soon-to-be Master Herbalist, and co-founder of Hikma Rituals, a homegrown brand of botanicals including oils, tinctures and dusts. Hashem and Shereen discuss the beginnings of her journey into herbalism by way of a rose infusion ritual, the desire to reclaim her Iraqi heritage, and the serendipitous meeting with Mahdiah El-Jed, her business partner and co-founder. Shereen talks about the challenges that Hikma Rituals faces going head-to-head with big Pharma and the wellness industry's good, bad and ugly. We also catch a glimpse of Shereen's efforts towards community building and the rewards she reaps by mending client ailments…and a bonding session with Hashem over cold water immersions! Here are the books Shereen mentioned on the episode: The flora of Iraq Shahina A. Ghazanfar, A Herbal of Iraq Prof. Aref Abu-Rabia, Indigenous Medicine Among the Bedouin in the Middle East Rania Abou Samra, Tania Tabar & Layla K. Feghali, Li Beirut | herbal + healing support guide Talitha Fanous: Sun Sisters: A Field Guide to Levant Flowers

In this podcast episode, the speaker reflects on the term “Al Hikma,” which appears repeatedly in the Quran and is often misunderstood. The speaker provides examples from the Quran that connect “Hikma” to legal ways... The post Taraweeh Reflections Day 2 – Ramadan 1444 Hijri first appeared on Islampodcasts.

In this podcast episode, the speaker reflects on the term “Al Hikma,” which appears repeatedly in the Quran and is often misunderstood. The speaker provides examples from the Quran that connect “Hikma” to legal ways... The post Taraweeh Reflections Day 2 – Ramadan 1444 Hijri first appeared on Islampodcasts. The post Taraweeh Reflections Day 2 – Ramadan 1444 Hijri appeared first on Islampodcasts.

Digging into last year's performance drivers, the current opportunity set, and benefits of resuming boots-on-the-ground research.   Highlights: A review of the market and our strategy's performance in 2022 and three key learnings Why we exited Kakao, and some of the new additions to the portfolio: Salik, Vesta Risks we're monitoring—and managing: China-U.S. tensions over Taiwan and geographic exposure in the portfolio The power of pricing power (see: TSMC) and types of ESG considerations that we look for in our investments (Petro Rio) How a shared investment philosophy and process makes for better decision making—e.g., Lonza, Hikma

We're days away from the final batch of episodes of Netflix's 'Love is Blind' but before we get there, this week Mariah and Hikma join the show to discuss our thoughts on the couples. We want to be clear this is a spoiler filled episode with us giving our opinions on what we've seen on the show.  Follow us on Instagram and on Twitter.

Netflix is back with a reality dating show, this time with couples going through ultimatums.  Warning, we get right into spoilers. If you're still watching the show, come back to this episode after you complete the first season. Here to unpack the reunion and the season are two good friends of mine, we go back decades: Hikma and Mariah. We talk about the "realest" couple, the most toxic, and so much more. Please rate, review, follow and subscribe. Follow us on Instagram and Twitter.

or Love is Blurry? What a reunion! Here to unpack the reunion and the season are two good friends of mine, we go back decades. Andranee, Hikma, and I get in to the second season of the Netflix dating show and how it doesn't compare to the first but we're still hooked. Also, what's up with Shake? If you don't mind, can you leave a review of the show? Why? It's the best way of spreading the show, allowing new people to find us. Thanks. Please rate, review, follow and subscribe. Follow us on Instagram and Twitter.

In this episode Tariq from the Youtube channel Hikma History joins us to talk about the Modernization of Afghanistan. How did the process go? What went wrong? How did it go wrong, for Afghanistan to end up as the country we know it as today? Find out in this weeks episode of "Well That Aged Well", With "Erlend Hedegart".Link to Hikma history Youtube Channel: https://www.youtube.com/c/HikmaHistoryFind him on instagram under: Hikma historySupport this show http://supporter.acast.com/well-that-aged-well. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.

In this episode of The Straight Up Start Up our guest, Lana Ghanem Walks us through her career journey and how she ended up in the venture capital world of the Health industry, Lana explains what she does every day to support innovation within startups how she incorporates it as a new innovative method to be adopted in the Life sciences world.Lana is the Managing Director of Hikma Ventures (the corporate VC arm of Hikma Pharmaceuticals PLC) which she helped establish in 2015. Prior to joining Hikma, Lana worked as a Financial Analyst in the Mergers and Acquisitions department at Dresdner Kleinwort Investment Bank in London where she worked on transactions for clients across multiple industries.في هذه الحلقة من  ، تشرح لنا لانا غانم عن رحلتها المهنية وكيف انتهى بها المطاف في عالم رأس المال الاستثماري في القطاع الصحي ، تشرح لانا ما تفعله كل يوم لدعم الابتكار داخل الشركات الناشئة وكيف تدمج الابداع في شركات القطاع الصحي اتمت لانا تعيلمها الجامعي في جامعة Mcgill وبعدها حصلت على ماجستير في ادارة الاعمال من جامعة هارفرد بدأت ضيفتنا كمساعد المدير التنفيذي وكرئيسة قسم الاستراتيجيات والتطوير في شركة الحكمة لادوية حيث عملت على العديد من الاستراتيجيات وعلى تطوير العديد من الاقسام في الشركة مثل قسم العمليات والمالية والدمج وحاليا هي المدير الاداري لحكمة فنتشرز والتي هي فرع رأس المال المخاطر لشركة الحكمة لادوية حيث تقوم بالاستثمار بالشركات الناشئة في مجال التكنولوجيا الصحية